Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Payables (2016 - 2025)

Historic Payables for Sanara MedTech (SMTI) over the last 15 years, with Q3 2025 value amounting to $1.1 million.

  • Sanara MedTech's Payables fell 1241.53% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 1241.53%. This contributed to the annual value of $1.5 million for FY2024, which is 2205.3% down from last year.
  • According to the latest figures from Q3 2025, Sanara MedTech's Payables is $1.1 million, which was down 1241.53% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Sanara MedTech's Payables registered a high of $2.1 million during Q1 2025, and its lowest value of $280321.0 during Q1 2021.
  • Over the past 5 years, Sanara MedTech's median Payables value was $1.1 million (recorded in 2025), while the average stood at $1.1 million.
  • Its Payables has fluctuated over the past 5 years, first plummeted by 5831.98% in 2021, then skyrocketed by 23153.92% in 2022.
  • Sanara MedTech's Payables (Quarter) stood at $438154.0 in 2021, then skyrocketed by 217.86% to $1.4 million in 2022, then surged by 38.15% to $1.9 million in 2023, then fell by 22.05% to $1.5 million in 2024, then dropped by 24.0% to $1.1 million in 2025.
  • Its Payables was $1.1 million in Q3 2025, compared to $1.5 million in Q2 2025 and $2.1 million in Q1 2025.